REG - Proteome Sciences - AGM Statement

Proteome SciencesAnnouncement

05/05/2021 11:00

RNS Number : 6322X
  
Proteome Sciences PLC
  
05 May 2021
  
 

5 May 2021
 
 
 
 
Proteome Sciences plc
("Proteome Sciences" or the "Company") 
 
Annual General Meeting (AGM) Statement 
 
At the Company's AGM being held today at 11.00 am, the Chairman, Christopher Pearce, will make the following statement:
 
"Having closed 2020 with a strong final quarter and order book carried forward, we are pleased to report that the same pattern has continued during the first quarter of 2021. We expect further growth from the services business and TMT Pro™, assuming that the general economic background continues to return more to normality in the second half of 2021."  Ends
 
 
 
For further information:
 



Proteome Sciences plc 




Dr Mariola Soehngen, Chief Executive Officer
Dr Ian Pike,  Chief Scientific Officer
 
 




Tel: +44 (0)20 7043 2116




Allenby Capital Limited (AIM Nominated Adviser & Broker)  




John Depasquale / Jeremy Porter 


Tel: +44 (0) 20 3328 5656



 
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
AGMAAMLTMTIMMLB